Renal denervation trial 'flawed'

The effectiveness of renal denervation has been called into question ever since the SYMPLICITY HTN-3 trial was halted due to lack of efficacy, despite early open-label registry trials showing the procedure had significant and durable reductions in blood pressure in certain patients with resistant hypertension.

Senior director at the Baker IDI Heart and Diabetes Institute, Professor Murray Esler who was a co-author on the new review, said SIMPLICY HTN-3 was, in short, a failure but it has had a lasting damaging effect on perceptions about the procedure. 

"The study put a stop to renal